Treatment Options for Juvenile Idiopathic Arthritis (JIA) Associated Uveitis
| Autor: | Douglas A. Jabs, Manfred Zierhut, Dana M. Hornbeak, Jennifer E. Thorne, Elisabetta Miserocchi, Rowayda Mohamed Amin |
|---|---|
| Přispěvatelé: | Amin, Rm, Miserocchi, E, Thorne, Je, Hornbeak, D, Jabs, Da, Zierhut, M |
| Rok vydání: | 2015 |
| Předmět: |
medicine.medical_specialty
genetic structures Visual impairment Arthritis Disease 03 medical and health sciences 0302 clinical medicine medicine Immunology and Allergy Juvenile Humans Prospective Studies Glucocorticoids 030203 arthritis & rheumatology business.industry Pediatric uveitis Treatment options medicine.disease Dermatology Uveitis Anterior Arthritis Juvenile Biological Therapy Ophthalmology Treatment modality Chronic Disease 030221 ophthalmology & optometry Physical therapy medicine.symptom business Uveitis Immunosuppressive Agents |
| Zdroj: | Ocular immunology and inflammation. 24(1) |
| ISSN: | 1744-5078 |
| Popis: | Purpose: To summarize the available published data regarding the treatment of JIA-associated chronic uveitis. Methods: Available peer-reviewed publications regarding the treatments of JIA-associated uveitis were read by multiple authors (RMA, EM, JET, and DH) and the data from these reports were synthesized for this review. Results: Juvenile idiopathic arthritis (JIA)-associated chronic uveitis is a significant cause of ocular morbidity and visual impairment in children, often resulting in more frequent complications and worse visual outcomes than other types of pediatric uveitis. Since not all patients respond to the first medication introduced, it is useful to have a wide range of available treatment modalities to address recalcitrant disease. Treatment options for JIA-associated uveitis have increased substantially over the past decade, particularly with the availability of newer biological agents in addition to established medication classes such as anti-inflammatories (including topical and systemic corticosteroids) and antimetabolites. Conclusions: Although data are increasing regarding biologic agents, definitive randomized prospective clinical trials would be helpful to determine their optimal dose, frequency, treatment duration, and long-term safety in children. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|